A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus

Palmarisa Franchetti, Ghassan Abu Sheikha, Loredana Cappellacci, Stefano Marchetti, Mario Grifantini, Emanuela Balestra, Carlo Federico Perno, Umberto Benatti, Giorgio Brandi, Luigia Rossi, Mauro Magnani

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The most common therapies against human herpes virus (HSV-1) and human immunodeficiency virus (HIV-1) infectivity are based on the administration of nucleoside analogues. Acyclovir (ACV) is the drug of choice against HSV-1 infection, while the acyclic nucleoside phosphonate analogue PMPA has shown marked anti-HIV activity in a phase I and II clinical studies. As monocyte- derived macrophages are assumed to be important as reservoirs of both HSV-1 and HIV-1 infection, new approaches able to inhibit replication of both viruses in macrophages should be welcome. ACVpPMPA, a new heterodinucleotide consisting of both an antiherpetic and an antiretroviral drug bound by a phosphate bridge, was synthesized and encapsulated into autologous erythrocytes modified to increase their phagocytosis by human macrophages. ACVpPMPA-loaded erythrocytes provided an effective in vitro protection against both HSV-1 and HIV-1 replication in human macrophages. (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)149-158
Number of pages10
JournalAntiviral Research
Volume47
Issue number3
DOIs
Publication statusPublished - Sep 2000

Fingerprint

Human Herpesvirus 1
Simplexvirus
HIV-1
Macrophages
HIV
Nucleosides
Erythrocytes
Organophosphonates
Acyclovir
Virus Replication
Phagocytosis
Pharmaceutical Preparations
HIV Infections
Phosphates
Viruses
Infection
ACVpPMPA
Therapeutics

Keywords

  • (R)PMPA
  • Acyclovir (ACV)
  • Anti-HIV activity
  • Anti-HSV activity
  • Human macrophages

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Franchetti, P., Abu Sheikha, G., Cappellacci, L., Marchetti, S., Grifantini, M., Balestra, E., ... Magnani, M. (2000). A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. Antiviral Research, 47(3), 149-158. https://doi.org/10.1016/S0166-3542(00)00101-7

A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. / Franchetti, Palmarisa; Abu Sheikha, Ghassan; Cappellacci, Loredana; Marchetti, Stefano; Grifantini, Mario; Balestra, Emanuela; Perno, Carlo Federico; Benatti, Umberto; Brandi, Giorgio; Rossi, Luigia; Magnani, Mauro.

In: Antiviral Research, Vol. 47, No. 3, 09.2000, p. 149-158.

Research output: Contribution to journalArticle

Franchetti, P, Abu Sheikha, G, Cappellacci, L, Marchetti, S, Grifantini, M, Balestra, E, Perno, CF, Benatti, U, Brandi, G, Rossi, L & Magnani, M 2000, 'A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus', Antiviral Research, vol. 47, no. 3, pp. 149-158. https://doi.org/10.1016/S0166-3542(00)00101-7
Franchetti P, Abu Sheikha G, Cappellacci L, Marchetti S, Grifantini M, Balestra E et al. A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. Antiviral Research. 2000 Sep;47(3):149-158. https://doi.org/10.1016/S0166-3542(00)00101-7
Franchetti, Palmarisa ; Abu Sheikha, Ghassan ; Cappellacci, Loredana ; Marchetti, Stefano ; Grifantini, Mario ; Balestra, Emanuela ; Perno, Carlo Federico ; Benatti, Umberto ; Brandi, Giorgio ; Rossi, Luigia ; Magnani, Mauro. / A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus. In: Antiviral Research. 2000 ; Vol. 47, No. 3. pp. 149-158.
@article{94b9a193f2b04c39909d0dc4f915044d,
title = "A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus",
abstract = "The most common therapies against human herpes virus (HSV-1) and human immunodeficiency virus (HIV-1) infectivity are based on the administration of nucleoside analogues. Acyclovir (ACV) is the drug of choice against HSV-1 infection, while the acyclic nucleoside phosphonate analogue PMPA has shown marked anti-HIV activity in a phase I and II clinical studies. As monocyte- derived macrophages are assumed to be important as reservoirs of both HSV-1 and HIV-1 infection, new approaches able to inhibit replication of both viruses in macrophages should be welcome. ACVpPMPA, a new heterodinucleotide consisting of both an antiherpetic and an antiretroviral drug bound by a phosphate bridge, was synthesized and encapsulated into autologous erythrocytes modified to increase their phagocytosis by human macrophages. ACVpPMPA-loaded erythrocytes provided an effective in vitro protection against both HSV-1 and HIV-1 replication in human macrophages. (C) 2000 Elsevier Science B.V.",
keywords = "(R)PMPA, Acyclovir (ACV), Anti-HIV activity, Anti-HSV activity, Human macrophages",
author = "Palmarisa Franchetti and {Abu Sheikha}, Ghassan and Loredana Cappellacci and Stefano Marchetti and Mario Grifantini and Emanuela Balestra and Perno, {Carlo Federico} and Umberto Benatti and Giorgio Brandi and Luigia Rossi and Mauro Magnani",
year = "2000",
month = "9",
doi = "10.1016/S0166-3542(00)00101-7",
language = "English",
volume = "47",
pages = "149--158",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - A new acyclic heterodinucleotide active against human immunodeficiency virus and herpes simplex virus

AU - Franchetti, Palmarisa

AU - Abu Sheikha, Ghassan

AU - Cappellacci, Loredana

AU - Marchetti, Stefano

AU - Grifantini, Mario

AU - Balestra, Emanuela

AU - Perno, Carlo Federico

AU - Benatti, Umberto

AU - Brandi, Giorgio

AU - Rossi, Luigia

AU - Magnani, Mauro

PY - 2000/9

Y1 - 2000/9

N2 - The most common therapies against human herpes virus (HSV-1) and human immunodeficiency virus (HIV-1) infectivity are based on the administration of nucleoside analogues. Acyclovir (ACV) is the drug of choice against HSV-1 infection, while the acyclic nucleoside phosphonate analogue PMPA has shown marked anti-HIV activity in a phase I and II clinical studies. As monocyte- derived macrophages are assumed to be important as reservoirs of both HSV-1 and HIV-1 infection, new approaches able to inhibit replication of both viruses in macrophages should be welcome. ACVpPMPA, a new heterodinucleotide consisting of both an antiherpetic and an antiretroviral drug bound by a phosphate bridge, was synthesized and encapsulated into autologous erythrocytes modified to increase their phagocytosis by human macrophages. ACVpPMPA-loaded erythrocytes provided an effective in vitro protection against both HSV-1 and HIV-1 replication in human macrophages. (C) 2000 Elsevier Science B.V.

AB - The most common therapies against human herpes virus (HSV-1) and human immunodeficiency virus (HIV-1) infectivity are based on the administration of nucleoside analogues. Acyclovir (ACV) is the drug of choice against HSV-1 infection, while the acyclic nucleoside phosphonate analogue PMPA has shown marked anti-HIV activity in a phase I and II clinical studies. As monocyte- derived macrophages are assumed to be important as reservoirs of both HSV-1 and HIV-1 infection, new approaches able to inhibit replication of both viruses in macrophages should be welcome. ACVpPMPA, a new heterodinucleotide consisting of both an antiherpetic and an antiretroviral drug bound by a phosphate bridge, was synthesized and encapsulated into autologous erythrocytes modified to increase their phagocytosis by human macrophages. ACVpPMPA-loaded erythrocytes provided an effective in vitro protection against both HSV-1 and HIV-1 replication in human macrophages. (C) 2000 Elsevier Science B.V.

KW - (R)PMPA

KW - Acyclovir (ACV)

KW - Anti-HIV activity

KW - Anti-HSV activity

KW - Human macrophages

UR - http://www.scopus.com/inward/record.url?scp=0343341718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343341718&partnerID=8YFLogxK

U2 - 10.1016/S0166-3542(00)00101-7

DO - 10.1016/S0166-3542(00)00101-7

M3 - Article

VL - 47

SP - 149

EP - 158

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 3

ER -